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doi:10.1016/j.pedneo.2011.02.001Background: Early-onset sepsis (EOS) is the major cause of neonatal morbidity and mortality.
Maternal group B Streptococcus (GBS) screening and intrapartum antibiotic prophylaxis (IAP)
were implemented in our hospital in 2004. Our aim was to evaluate the effectiveness of the
program and changes in pathogens and antibiotic susceptibility.
Methods: The medical charts of mothers and infants with EOS between January 2001 and
November 2008 were retrospectively reviewed. EOS was defined as sepsis occurring within
72 hours of birth. Data were pooled and compared for January 2001 through September
2004 (Period 1, without GBS screening) and October 2004 through November 2008 (Period 2,
with GBS screening and IAP).
Results: The GBS screening rate increased from 10.11% in 2004 to 65% in 2008 and the IAP rate
increased from 40% in 2004 to 90% in 2008. The most common EOS pathogen in Period 1 was GBS
(45.4%), which decreased to 20% in Period 2 (pZ 0.081; trend pZ 0.009). The percentage of
EOS because of Escherichia coli in Period 1 was 40.9% but increased to 70% in Period 2
(pZ 0.059). E coli EOS increased in extremely low birth weight premature babies weighing
500e1000 g from Period 1 to Period 2 (pZ 0.031). The incidence of ampicillin-resistant E colieonatology, Department of Pediatrics, Mackay Memorial Hospital, 92, Section 2, Chung Shan North Rd,
h.org.tw (C.-H. Hsu).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
Early-onset sepsis after GBS screening plus IAP 79EOS was relatively high, but no significant change (88.9% vs. 92.9%) after implementation of
GBS screening and IAP was noted.
Conclusion: GBS screening plus IAP is effective in decreasing the incidence of GBS EOS;
however, an increase in EOS caused by E coli was noted. Monitoring of pathogens causing
EOS is important for effective treatment.
Copyright ª 2011, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Early-onset sepsis (EOS) is the major cause of neonatal
morbidity and mortality.1,2 In the early 1990s, the American
Academy of Pediatrics (AAP) and the American College of
Obstetricians and Gynecologists issued a guideline for the
use of intrapartum antibiotic prophylaxis (IAP) to prevent
early-onset group B Streptococcus (GBS) infection.3 The
presence of two recommendations (risk-based screening vs.
culture-based screening) led to a consensus agreement by
the AAP, the American College of Obstetricians and Gyne-
cologist, and the Centers for Disease Control and Preven-
tion (CDC), for which guidelines were published in 1996.4e6
Since the adoption of the 1996 consensus guidelines for IAP
in the United States, the incidence of GBS EOS has declined
by 65% (1.7& to 0.6&).4,7 Maternal GBS screening plus IAP
has been used in Taipei Mackay Memorial Hospital (TPMMH)
since October 2004. To evaluate the changes of pathogens
and its antibiotic susceptibility, we reviewed the incidence
of EOS for the period before screening and IAP were
implemented, and since 2004, after screening and IAP were
implemented.
2. Methods
The medical charts of both mothers and their infants with
EOS from January 2001 to November 2008 were retrospec-
tively studied. Period 1 was defined as the period from 2001
through September 2004. During Period 1, GBS screening
and IAP were not performed. Period 2 was the period from
October 2004 to November 2008. In Period 2, GBS screening
and IAP were routinely performed. The incidence of inborn
EOS and culture screening rate from each period was
collected and analyzed.
All live born infants delivered at TPMMH with a birth
weight more than 400 g were enrolled in this study. EOS was
defined as a positive culture in blood drawn within 72 hours
after birth.8,9 Based on the definition of EOS by Stoll et al,9
bacteria isolates from blood that tested positive for Cory-
nebacterium sp, Diphtheroids sp, and Micrococcus were
considered to be contaminants and excluded from the anal-
ysis. These bacteria are usually nonpathogenic and can be
normal flora on the skin. For all other pathogens, sepsis was
defined by the presence of the organism in the blood culture.
For EOS with the presence of coagulase-negative
staphylococci (CONS), there is the concern of whether
blood isolates of CONS represent true sepsis or contami-
nation. In our hospital, we use a standard definition for
CONS EOS to rule out the possibility of CONS contamination.
The definition of CONS EOS is: (1) two consecutive bloodcultures show similar CONS isolates; (2) the neonate has
clinical symptoms and signs of infection; and (3) antibiotics
are prescribed for more than 5e7 days.
The choice of antibiotics used for IAP at TPMMH follows
the CDC and AAP guidelines.4e6 In brief, a loading dose of
2 g ampicillin intravenously is administered followed by 1 g
intravenously every 4 hours during labor. At least two doses
of ampicillin are required to be considered complete IAP.
No ampicillin-resistant GBS has been reported in our center.
There is no upper limit to the number of doses adminis-
tered. Penicillin G can be used as an alternative. If the
pregnant woman is allergic to ampicillin, cefazolin is used
as an alternative. Clindamycin or erythromycin will be used
if the patient has a history of penicillin allergy or a strong
penicillin skin test. If the GBS isolate is resistant to clin-
damycin or erythromycin, or susceptibility is unknown,
then vancomycin will be used. A flowchart of the GBS
screening and IAP policy is presented in Figure 1.
Data from Period 1 and Period 2 for GBS EOS and Escher-
ichia coli EOSwere comparedusing thec2 test/Fisher’s exact
test for categorical variables and the independent two-
sample t test for continuous variables. Trends during the
study periods were analyzed using the Cochran-Armitage
trend test. Statistical analyses were performed using SAS
software, version 9.1 (SAS Institute Inc., Cary, NC, USA).
Statistical significance was defined as p value less than 0.05.3. Results
Data from the period of 2004e2008 are presented in Table 1.
The GBS screening rate increased from 10.11% in 2004 to 65%
in 2008. The culture-positive GBS rate remained at around
22% from October 2004 to November 2008 and is similar to
that in the United States.9 The IAP rate increased from 40% in
2004 to 90% in 2008 among GBS screen-positive pregnant
women, whereas the cesarean section rate decreased from
34.7% in October 2004 to 12.1% in November 2008. The
percentage of women with risk factors (i.e., premature
rupture of membrane, maternal fever, and maternal cho-
rioamnionitis) who underwent GBS screening was low (0.2%),
suggesting that a risk-based GBS IAP policy would miss
a significant number of GBS-colonized women.
Between January 1, 2001 andNovember30, 2008, a total of
32,614 live born infantswere deliveredat TPMMH.Therewere
42 infants diagnosed to have EOS, 22 cases in Period 1 and 20
cases in Period 2 (Table 2). Themost common EOS pathogen in
Period 1 was GBS (incidenceZ 0.658&; 45.4% of EOS cases),
which decreased in Period 2 (incidenceZ 0.223&; 20% of EOS
cases). By contrast, the percentage of EOS because of E coli in
Period1was40.9%(incidenceZ 0.592&) but increased to70%
Recommend to do self-paid GBS culture and screen at wk 35-37. (Unless GBS bacteriuria has been 
examined in this pregnancy or previous neonate had severe GBS infection.) Patient education
delivered by OPD nurses
.
GBS (+) Previous neonate had 
severe GBS infection 
(regardless of the result of 
GBS screen in this 
pregnancy)
Unknown result of GBS screen (unscreened 
patients, incomplete screen, or unknown result)
Give birth
37 wk Rupture of membrane 
over 18 hr
Body temperature > 38˚C in the 
parturient period 
Give prophylactic Abx in the parturient period
(DR nurses follow the result of GBS culture, DR physicians determine the result of GBS culture)
1. Prenatal test 
(OPD)
2. Hospitalized 
pregnant women Gestation < 37 wk with premature uterine contraction or premature rupture of membrane* 
Has never had GBS screen GBS (+) GBS (-)
GBS culture
plus Abx given  
Give Abx at least for 48 hr Abx is unnecessary
Negative result after 48
hr 
Stop Abx
If childbirth doesn’t occur after 4 
wk, 
GBS screen should be repeated
Abx given again
in the parturient period 
GBS rapid test
plus Abx given
Negative result after 2
hr
Stop Abx
GBS (+)
Might give birth >48 hr Might give birth <48 hr
Give birth > 37 wk 
Figure 1 GBS screening process in the Department of Obstetrics and Gynecology, Mackay Memorial Hospital. Note: (1) GBS bacteriuria culture is not a regular procedure for
prenatal testing, so this procedure cannot 100% rule out GBS infection in neonates; (2) GBS rapid test is only a reference, and GBS culture is diagnostic; (3) Recommended
medications: First-line, penicillin G and ampicillin; Second-line, cefazolin; Third-line, clindamycin and erythromycin; Fourth-line, vancomycin; (4) Antibiotics are not recom-
mended in situations listed below: (a) GBS (þ) in the previous pregnancy but GBS () in this pregnancy; (b) If cesarean section is performed without labor or rupture of
membranes, the consideration of the results of GBS screen is unnecessary; (c) The result of the GBS screen is negative, although there is a risk factor in the parturient period (such
as premature birth, rupture of membrane, or fever); (5) If infection or fever occurs in pregnancy or rupture of membrane occurs earlier than the 37th week, general bacterial
culture of the cervix or vagina in addition to GBS screening should be considered. ABxZ antibiotics; GBSZ group B Streptococcus; OPDZ outpatient department.
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Table 1 Inborn early-onset sepsis and culture screen rate from 2004 to 2008
2004* 2005 2006 2007 2008*
Total live births 1108 3773 4213 4413 3898
Total screens 112 1001 1839 2434 2521
Screen rate (%) 10.11 25.83 42.8 59 65
GBS screening positive, n (%) 23 (20.54) 203 (20.28) 367 (19.9) 495 (20.3) 447 (22.9)
IAP rate (%) 40 55 83 88.4 90.0
With risk factor, n (%)y 5 (4.4) 16 (7.8) 35 (9.5) 6 (1.2) 1 (0.2)
Cesarean section rate, n (%)z 8 (34.7) 33 (16.2) 46 (12.5) 60 (14.5) 54 (12.1)
* The year 2004 includes the months of October, November, and December; 2008 includes the months of January through November
y Risk factors include intrapartum fever 38C, PROM 18 hr, and chorioamnionitis
z Percentage is calculated by the cesarean section rate in culture-positive women.
GBSZ group B Streptococcus; IAPZ intrapartum antibiotic prophylaxis; PROMZ premature rupture of membrane.
Early-onset sepsis after GBS screening plus IAP 81in Period 2 (incidenceZ 0.804&). There was no significant
difference in E coli incidence between the two periods
(pZ 0.059). Moreover, therewas a relatively high percentage
of ampicillin-resistant E coli EOS; 88.9% (8/9) and 92.9% (13/
14) for Periods 1 and 2, respectively. However, there was no
significant difference between the two periods (pZ 0.503)
(Table 3). Furthermore, therewas a significant increase in the
incidence of E coli EOS in extremely low birth weight (ELBW)
premature babies weighing 500e1000 g; 1.7% for Period 1 and
5.8% for Period 2 (pZ 0.031) (Table 3).
The incidence of GBS EOS decreased dramatically from
2001 to 2007 (trend pZ 0.009, Figure 2). When the trend
incidence of GBS EOS throughout the whole study period was
calculated, three GBS EOS cases in 2008 were excluded
because the guidelines for GBS screening and IAP were not
followed. In 2004, 2006, and 2007, the inborn GBS incidence
was zero in our hospital, suggesting that a GBS screening
strategy with IAP can effectively reduce GBS EOS. In 2008,
there were three GBS EOS cases. In one case, maternal GBS
screening was not performed because the mother was not
able to afford the self-paid screening examination. In
another, the IAP was incomplete (only one dose of ampicillin
was administered before delivery because of precipitous
labor). In the last case, a cesarean section was performed,
thus per the guidelines, no IAP was administered.Table 2 Incidence of inborn early-onset sepsis from January 20
Period 1 (nZ 22)
n Incidence (&) Ratio (%)
Gram-positive organisms
GBS 10 0.658 45.4
Enterococcus* 1 0.066 4.5
MSSA 2 0.132 9.1
Gram-negative organisms
E coliy 9 0.592 40.9
Fungus
Fungi* 0 0 0
* The p values are based on Fisher’s exact test.
y The p values are based on c2 test.
Period 1: January 2001 to September 2004; total live birthsZ 15,209
Period 2: October 2004 to November 2008; total live birthsZ 17,405.
GBSZ group B Streptococcus; MSSAZmethicillin-sensitive StaphylocDuring the study period (2001e2008), there were two
CONS isolates from newborns. However, neither of the
infants had clinical signs or symptoms of sepsis nor the
repeated blood cultures yielded pathogens. Accordingly,
we presumed that the blood culture positive for CONS was
because of contamination.4. Discussion
Since the adoption of the 1996 consensus guidelines for IAP
in the United States, the incidence of GBS EOS sepsis has
declined by 65% (1.7&e0.6&).4,7 In this study, we
compared the incidence, pathogens, and risk factors asso-
ciated with EOS before and after a GBS screening and IAP
policy was implemented. We found that the implementa-
tion of the policy resulted in an increase in the screening
rate and IAP rate. In 2008, the GBS screen-positive rate in
our hospital was 22.9%, and 90% of the GBS-positive women
received IAP, which is very similar to that in the United
States.10,11 Of particular note, only 0.2% of the GBS-colo-
nized pregnant women had risk factors (intrapartum fever
 38C, premature rupture of membrane  18 hours, cho-
rioamnionitis), whereas the GBS colonization rate in
healthy pregnant women was approximately 22%. This01 to November 2008
Period 2 (nZ 20) p*
n Incidence (&) Ratio (%)
4 0.223 20 0.081
1 0.057 5 1.000
0 0 0 0.489
14 0.804 70 0.059
1 0.057 5 0.476
.
occus aureus.
Table 3 Inborn E coli early-onset sepsis from January 2001 through November 2008 by birth weight
Period 1 Period 2 p*
Number infected/total number Number infected/total number
Birth weight (g)
<500 0/14 0/10 e
500e1000 5/296 8/138 0.031*
1000e1500 1/380 0/275 1.000
1500e2000 1/409 3/442 0.625
>2000 2/14,110 3/16,540 1.000
Ampicillin-resistant E coli 8/15,209 13/17,405 0.513
Total E coli early-onset sepsis 9/15,209 14/17,405 0.395
Percentage of ampicillin-resistant E coli 88.9% 92.9% 1.000
* The p values are based on Fisher’s exact test.
Period 1: January 2001 to September 2004.
Period 2: October 2004 to November 2008.
82 C.-Y. Lin et alsuggests that a risk factor-based strategy for IAP may miss
a number of infants who may develop GBS EOS but whose
mothers have no recognizable risk factors.12
The incidence of GBS EOS decreased significantly from
2001 to 2007 (trend pZ 0.009). The inborn GBS incidence
was zero at our hospital in 2004, 2006, and 2007, suggesting
that the IAP policy effectively reduced GBS EOS. It is worthy
of note that in this study, we found that after 2 years
without any cases of inborn GBS EOS, three cases occurred
in 2008. We found that those cases were a result of failure
to comply with the GBS screening and IAP strategy, which
reflects the importance of carrying out the policy without
any compromise. In the first case of GBS EOS in 2008, the
mother was unable to afford the self-paid GBS screening
examination, and the baby contracted EOS GBS infection
after a vaginal delivery. In Taiwan, GBS screening is a self-
paid service and there are many women who cannot afford
the test. Hence, there is a desperate need for the national
audit of the screening policy and its performance. In the
second case, the mother has failed to receive complete IAP
(she received only one dose of parenteral ampicillin within0
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Figure 2 Incidence of inborn group B Streptococcus and Escherich
onset sepsis; GBSZ group B Streptococcus.4 hours before delivery.) Review of the mother’s medical
record indicated that she arrived at the hospital 3 hours
before giving birth, thus her labor was too short for
complete IAP. In the last case, a cesarean section was
performed, so no IAP was administered. The woman did not
receive IAP because our policy (based on the CDC and AAP
guideline) does not include women undergoing cesarean
section. Whether the neonate was infected because of the
prolong labor or during the cesarean section is unknown,
but one may consider extending the IAP policy to women
who receive a cesarean section for dysfunctional labor.
According to the current AAP GBS prophylactic guidelines,
women who undergo a cesarean section are at low risk of
GBS infection; nonetheless, as shown in our study, infection
can still occur.
A study by Liao et al13 reviewed the clinical presentations
associated with GBS infections in children between 1980 and
2000. Of the 25 infections during the study period, 36% (9)
were early-onset disease, 48% (12) were late onset, and 16%
(4) occurred after the third month of life. There were eight
strains tested for antibiotic sensitivity and all of them were2005 2006 2007 2008
ber of births)
E. coli
(3773) (4213) (4413) (3898)
ia coli EOS from January 2001 to November 2008. EOSZ early-
Early-onset sepsis after GBS screening plus IAP 83susceptible to penicillin, ampicillin, ceftaxime, and vanco-
mycin suggesting that GBS and IAP should be used to prevent
EOS inTaiwan. A recent studyofWuet al14 reviewedneonatal
sepsis occurringbetween January2001andDecember2006 in
the neonatal intensive care unit of National Taiwan Univer-
sity Hospital and found that most of the neonates with EOS
were term infants,whereas very lowbirthweight (VLBW) and
preterm infants accounted for most cases of late onset
sepsis. The most common pathogen was GBS (36%) followed
by E coli (26%), suggesting that pathogens other than GBS,
such as E coli, should be monitored.
In our study, E coli sepsis tended to increase throughout
the study period, although the increase was not statistically
significant. However, we found an increase in E coli EOS
incidence in ELBW premature babies weighing 500e1000 g,
1.7% for Period 1 and 5.8% for Period 2 (pZ 0.031) (Table
3). This observation is similar to that of previous reports
by Koenig15 and Stoll et al,16 which found that universal
screening measures and IAP have resulted in a dramatic
decrease in GBS, but an increase of gram-negative organ-
isms, as a cause of EOS in VLBW infants. Bizzarro et al17
studied neonatal E coli sepsis at Yale-New Haven Hospital
over the period from 1979 to 2006. The study period was
divided into three periods: 1917e1992, no formal IAP;
1993e1996, risk factor-based IPA; 1997e2006, screening-
based IAP. In VLBW (<1500 g) infants, increases in E coli
EOS, intrapartum ampicillin exposure, and ampicillin-
resistant E coli were observed from 1979 to 2006. They
postulated that intrapartum antibiotic exposure is
contributing to evolving trends in early neonatal sepsis.
An increasing trend in E coli EOS among VLBW neonates
since the introduction of GBS prophylactic therapy has been
observed.8,9,18 Some studies have raised concerns regarding
the possible effects of GBS screening plus IAP on changes in
antibiotic susceptibilities of E coli in EOS.19e21 In an analysis
of data (1998e2000) from San Francisco and Atlanta for the
CDC Active Bacterial Core surveillance,22 the rate of
ampicillin resistance in EOS attributable to E coli in preterm
infants increased from 29% (2 of 7 infants) in 1998 to 84%
(16 of 18 infants) in 2000. Conversely, Schrag et al23
reported a lack of an association between IAP and EOS
attributable to ampicillin-resistant E coli. In our hospital,
before the implementation of the GBS screening policy
(i.e., between 2001 and 2004), the average incidence of E
coli sepsis was low (0.592&), but after the GBS screening
policy was introduced, the E coli EOS rate increased to
approximately 1.4& in 2007 and 2008 (Figure 2); however,
the trend p value was not statistically significant
(pZ 0.059). Although there was no significant difference in
overall E coli incidence between the two periods, the
percentage of EOS because of E coli increased from in
Period 1 to Period 2, as did the incidence of E coli in EOS
ELBW premature baby. Based on our observation, we
suggest that the changes in pathogens causing EOS and
antibiotic susceptibility require close monitoring.
Bizzarro et al17 suggested that exposure, both frequent
and prolonged, to broad-spectrum antibiotics for the
treatment of chorioamnionitis and maternal infections at
any gestational age may alter maternal microbiological
flora. This change may result in colonization with poten-
tially pathogenic bacteria, thus increasing the rates of
neonatal sepsis to antibiotic resistant organisms. Inaddition, the presence of drug-resistance E coli acquired
from the environment in the gut of the mother is possible.
Data from the CDC in 2005 showed a continued decrease in
the annual incidence of early-onset GBS infection world-
wide after implementation of IAP.24 Nevertheless, some
authors have suggested that a new strategy of IAP for E coli
EOS is needed. Friedman et al25 suggested that for the
women who received intrapartum ampicillin before
delivery, current empiric management of neonatal sepsis
requires reevaluation given changing antimicrobial suscep-
tibilities. There are no articles in the literature that
specifically discuss about the strategies of IAP for E coli EOS
in Taiwan or other countries. Reports investigating the
emerging antimicrobial-resistant Gram-negative pathogens
in Taiwanese hospitals, however, have pointed out that
antimicrobial-resistant E coli has been rising in response to
increased use of extended spectrum cephalosporins in
health care settings.26 It is clear that the changes in path-
ogens causing EOS and antibiotic susceptibility require
close monitoring.27 In our study, we observed a fluctuation
in the incidence of E coli infections during the study period
and a high incidence of ampicillin-resistant infections
(88.9% vs. 92.9% for Period 1 and 2, respectively, pZ 0.503;
Table 3), which highlights the necessity of continuous
surveillance of EOS pathogens and antibiotic susceptibility.
The fluctuations in the incidence of E coli infections during
the study period, and a high incidence of ampicillin-resis-
tant infections, suggest the need for routine surveillance
for neonatal EOS. In our institute, sepsis workup, including
complete blood count, C-reactive protein level, and blood
cultures is performed for a neonate who has potential for
infection. From the public health point of view, a national
registry system should be established to effectively monitor
dynamic changes in EOS pathogens and occurrence of
antibiotic-resistant strains.
Some limitations of the study should be considered.
Since the incidence of inborn EOS from January 2001
through November 2008 was low, the case number was
relatively low; thus, the statistical analysis may not have
sufficient power to draw definitive conclusions. However,
we have carefully collected and analyzed the data, which
revealed some significant information and trends in early-
onset GBS infection. Whether the increased incidence of
ampicillin-resistant E coli EOS is resulted from GBS
screening plus IAP policy requires ongoing evaluation.
5. Conclusions
GBS screening with IAP policy is effective in decreasing the
incidence of GBS EOS; however, an increase in EOS caused
by E coli, especially among ELBW premature babies is
observed. Further surveillance of organisms causing EOS
and antibiotic susceptibility is needed.References
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